Showing 1‐10 of 500
Corporate
12 Dec 2024
​​Lonza Investor Update 2024​ Outlines Strategy, New Organizational Structure and Guidance
Lonza has provided an overview of its new “One Lonza” strategy and new organizational structure
Biologics
12 Nov 2024
Lonza to Expand Bioconjugation in Visp (CH) with Two Additional Manufacturing Suites
The expansion of bioconjugation capabilities will provide additional manufacturing capacity for launch and commercial supply, addressing growing market demand 2,000m2 of...
Corporate
24 Oct 2024
Q3 2024 Qualitative Update: Lonza Confirms Full-Year Outlook 2024
Outlook 2024 confirmed: Flat year-on-year sales in CER and a CORE EBITDA margin of high 20s  Strong commercial and operational performance across the CDMO business in...
Biologics
22 Oct 2024
Lonza Extends Collaboration with Major Pharmaceutical Partner for Integrated Commercial Supply of Antibody-Drug Conjugates
Extension of long-term collaboration includes construction of new customer-dedicated bioconjugation capacity in Visp (CH) and commercial antibody supply of a new ADC The...
Corporate
03 Oct 2024
Lonza Nominates David Meline as Independent Board Member
David Meline brings extensive governance, financial and industry experience to Lonza’s Board of Directors Olivier Verscheure will not stand for re-election at the 2025 Annual...
Biologics
01 Oct 2024
Lonza Completes Acquisition of Large-Scale Biologics Site in Vacaville (US) from Roche
The Vacaville site is one of the largest biologics manufacturing facilities in the world Acquisition extends Lonza’s US Biologics footprint with a significant presence on the...
Cell & Gene
24 Sep 2024
Lonza and Vertex Sign a Long-Term Commercial Supply Agreement for CASGEVY® (exagamglogene autotemcel)
Lonza to manufacture CASGEVY®, the world’s first CRISPR/Cas9 gene-edited cell therapy, for global commercial supply CASGEVY® will be manufactured at Lonza’s Geleen (NL) cell...
Corporate
28 Aug 2024
Lonza Prices EUR 1.2 Billion Dual-Tranche Straight Bonds
Basel, Switzerland, 28 August 2024 – Lonza Finance International NV, a wholly owned company of Lonza Group Ltd, Basel (“Lonza”), announced today the pricing of its dual tranche...
Corporate
25 Jul 2024
Lonza Nominates Juan Andres and Eric Drapé as Independent Board Members
Today, the Lonza Board of Directors announced the nomination of Juan Andres and Eric Drapé as Independent Members of the Board. The Board will propose to shareholders the election of both nominees at the Lonza Group Annual General Meeting (AGM) in May 202...
Corporate
25 Jul 2024
Lonza Group H1 2024 Performance Well On Track to Deliver Full-Year Outlook: Sales Up 1.8% CER and 29.2% CORE EBITDA Margin​
Lonza has reported sales of CHF 3.1 billion, growing 1.8% CER (-0.7% AER). CHF 893 million CORE EBITDA resulted in a robust margin of 29.2%, supported by favorable product mix and sustained demand for commercial CDMO services.
1 2 3 4 ... 50 >
Media Advisories

Updates for media on the latest products, offerings and developments across our business.

View all